Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

1 Wall Street Analyst Thinks AT&T Stock Is Going to $20. Is It a Buy?


AT (NYSE: T) stock has struggled in recent years, but Barclays analyst Kannan Venkateshwar believes the company deserves a higher valuation, considering the recent subscriber gains for its wireless and fiber services. The analyst upgraded AT stock from an equal weight (hold) rating to overweight (buy) but left the price target unchanged AT $20. This still represents upside of 18% from the current share price of $16.89.

Although investors usually buy telecom stocks for their dividends, AT has suffered from poor execution and uncertainty around the future of cable. It may offer shareholders an attractive 6.5% yield, but the stock has consistently underperformed the S 500, even on a total return basis. But the company's first-quarter earnings report showed new signs of life for the company.

Building on the previous quarter's gains, the company reported solid increases in postpaid phone and fiber subscribers in the first quarter. Revenue and adjusted earnings were slightly down year over year, but operating margin was up and free cash flow improved from $6.7 billion to $7.5 billion.

Continue reading


Source Fool.com

Allergy Therapeutics PLC Aktie

0,046 €
-20,00 %
Heute zeigt Allergy Therapeutics PLC einen starken Kursrückgang von -20,00 %.

Like: 0
T
Teilen

Kommentare